Navigation Links
Pfizer Animal Health Expands Global Commitment to a Safe Food Supply with a New Focus on Healthy Fish
Date:5/25/2010

production is becoming increasingly important in meeting global demand and is anticipated to account for 55% of total fish production by 2017, according to industry sources.  

"The time is right for Pfizer Animal Health to enter the global market for aquaculture healthcare therapeutics," said Juan Ramon Alaix, president, Pfizer Animal Health.  "The integration of Microtek R&D into Pfizer Animal Health also will allow us to build a more diverse and innovative portfolio in biopharmaceuticals.  The meat, dairy, egg and fish products that people enjoy for healthy living begin with a healthy food animal."

William Kay, Ph.D., president and chief executive officer, Microtek, who will continue to serve Pfizer in a consultant role, said, "Microtek not only brings to Pfizer Animal Health industry-leading vaccines and technology, but also complements Pfizer's portfolio of health services and diagnostics for food animal production."

Terms of Pfizer Animal Health's acquisition of Microtek were not disclosed.  

A growing Pfizer global commitment to safe food

According to Mr. Alaix, during the last three years, Pfizer Animal Health has continued to expand its commitment to a safe food supply.

In addition to acquiring last year a substantial portion of Wyeth/Fort Dodge Animal Health's biological and pharmaceutical R&D, manufacturing and food animal products and services, Pfizer Animal Health also:

  • Earlier this year, expanded into global, animal health generic medicines by acquiring R&D and a product line-up from Vetnex Animal Health Limited in India;
  • In 2008, established Pfizer Animal Genetics, helping breeders
    '/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
3. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund
6. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
7. WX Crowned Chemistry CRO of the Year by Pfizer
8. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
9. QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... and SHANGHAI , Aug. 31, ... company developing next-generation antibiotics, today announced positive top-line ... for its lead drug candidate MRX-I. MRX-I is ... bacteria such as MRSA and VRE, while offering ... therapeutic option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... CAESAREA, Israel , Aug. 31, 2015 /PRNewswire/ ... the Dario™ Diabetes Management Solution, today announced it ... $2.5 million. Funds will be used to support ... of the Dario, a mobile, cloud-based, diabetes management ... a stylish, ,all-in-one, pocket-sized, blood glucose monitoring device, ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... as a high priority in the drug development approval process. Thus, innovator companies ... This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2